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Abstract The objective of this study is to assess the
feasibility of transoral laser microsurgery (TLM) in the
treatment of squamous cell cancer of the tonsil and to
report the oncological and functional outcomes, using ret-
rospective chart review in the setting of single-institute,
academic tertiary referral center. Between October 1987
and December 2006, 102 patients were eligible for this
study, mostly suffering from advanced disease: 13 % pre-
sented with stage I and II (UICC/AJCC 2002) tumors and
87 % with stages III and IVa. The median follow-up was
63 months. All patients were treated by TLM with (or
without) neck dissection (95 %) and with (66 %) postop-
erative radiotherapy. Overall survival, recurrence-free
survival, disease-free survival, local control and loco-
regional control were analyzed as end points. Rate of tra-
cheotomies, postoperative complications and swallowing
function were also analyzed. 5-year Kaplan–Meier local
and loco-regional control was 78 % for pT1 and pT2 and
75 % for pT3 and pT4a tumors. 5-year Kaplan–Meier
disease-free survival, recurrence-free survival, and overall
survival and was 74, 64 and 59 % for stage I and II, 68, 60
and 56 % for stage III and IVa, respectively. Our data
supports the conclusion, that TLM should be considered as
a therapeutic option for the treatment of cancer of the
tonsil. The oncological and functional results are compa-
rable to any other treatment regimen, while the morbidity
and complications tend to be lower.
Keywords Transoral laser microsurgery  Carcinoma of
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Introduction
Squamous cell carcinoma (SCC) of the tonsil is one of the
most common types of cancer in the oropharynx world-
wide. Within the United States it accounts for over 12 % of
all head and neck cancers and in most cases is diagnosed at
an advanced stage [1]. Where the incidence reaches 20 %,
tonsillar carcinoma is the most significant subgroup of
oropharyngeal cancer [2]. Incidence of oropharyngeal
cancer strongly correlates to the consumption of alcohol
and tobacco [3]. Furthermore, the incidence of carcinoma
of the tonsil has significantly increased over the last
10 years, particularly in a younger age group, as a conse-
quence of human papilloma virus (HPV) [4].
The available treatment options for tonsillar cancer are
open surgery, endoscopic transoral surgical approaches and
non-surgical procedures. Depending on the tumor size and
the defect following tumor resection, open surgical pro-
cedures can range from a simple resection with primary
closure to local or regional flaps and finally to microvascular
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free flaps. However, postoperative loss of function, especially
swallowing, is directly associated to the extent of resection
and reconstruction [5]. In addition, surgery in most cases is
followed by adjuvant radiotherapy, which adds to the post-
operative morbidity. Radical surgical procedures have not
been proved to increase overall survival of the patients and
therefore other therapeutic options have gained importance.
Primary radiotherapy, which can be combined with
simultaneous chemotherapy, or induction chemotherapy
offers a non-surgical option with salvage surgery for any
failure. This organ preserving non-surgical approach is
widely favored, especially in the treatment of advanced
disease, as oncological results are reported to be compa-
rable to those achieved by open surgery with reconstruc-
tion, while morbidity and severe or fatal complications are
reported to be lower [6–9]. However, many patients
undergoing this treatment develop severe swallowing dis-
turbances including aspiration pneumonia. High-dose
chemoradiotherapy protocols have high rates of acute and
late toxicity affecting the upper aero-digestive tract func-
tion with notable rates of morbidity and mortality.
Transoral laser microsurgery (TLM) is a surgical alter-
native for all tumor categories of the upper aero-digestive
tract [10–13] and was introduced by Steiner [10] in the
early eighties. It provides the surgeon with a procedure that
has the advantage of accurate tumor resection under high
microscopic magnification without the need for recon-
struction procedures. For early stage carcinoma, the mini-
mum excision should be at least a tonsillectomy, and
usually an excellent exposure can be achieved when
treating tonsillar cancer. The patient is placed in a low
Trendelenburg position, and the region of interest is
exposed with appropriate gags and tongue depressors [14].
The Steiner distending oro-pharyngoscope can be used to
gain a better view and access to tonsil carcinomas infil-
trating the base of tongue and the vallecula.
Patients and methods
The majority of patients presenting with carcinoma of the
tonsil were treated exclusively by TLM with a transoral
approach. The exceptions were those patients with very
advanced tumors with extension to the carotid artery or to the
skull base. These patients cannot be safely treated by an
entirely endoscopic approach and required a combined trans-
oral and open transcervical approach. Previously untreated
tumors were staged according to the current classification of
the Union for International Cancer Control (UICC) and the
American Joint Committee on Cancer (AJCC) [15].
Exclusion criteria for this study were non-SCC tumors,
simultaneous second primary tumor patients, those with
simultaneous distant metastases, and N3 neck disease.
This retrospective study comprised 102 patients which
presented with SCC of the tonsil (T1–4, N0–2, M0) and
which were treated (October 1987–December 2006) by
TLM with curative intent. During the time of the presented
patient group (1987–2007), the importance of HPV and the
surrogate marker p16 had not fully come to light and
therefore has not been evaluated routinely.
Of these patients, 82 were male (80 %) and 20 were
female (20 %). The median age was 57 years, with a range
from 30 to 82 years. All patients were followed for at least
24 months, the median follow-up period being 63 months.
Stage distribution was as follows: stage I, 3 patients (3 %),
stage II, 10 patients(10 %), stage III, 29 patients (28 %)
and stage Iva, 60 patients (59 %). 22 patients presented
with a pT1 tumor category (22 %), 24 with pT2 (24 %), 42
with pT3 (41 %) and 14 with pT4a (13 %).
Pretherapeutic assessment consisted of a microscopic
and rigid or flexible endoscopic examination in the out-
patient clinics, followed by sonographic examination of the
neck. Computed tomography (CT) or magnetic resonance
imaging (MRI) of the neck was undertaken unless the
patient presented with satisfactory imaging performed at
the referring hospital. Further, standard preoperative
investigations included X-ray examination of the chest and
ultrasonography of the abdomen.
Panendoscopy was performed under general anesthesia
at the beginning of the surgical procedure to exclude any
second primary tumor in the aero and upper digestive tract.
In contrast to the classic en bloc resection, the tumor was
then resected in a step by step procedure under microscopic
magnification using a CO2 laser (40c, Lumenis, Dreieich,
Germany) in continuous, superpulse mode [14], average
power 6 W. Using this technique the surgeon follows and
completely excises the tumor, while preserving as much
healthy and functionally important tissue as possible. The
cutting characteristics of the CO2 laser within the tissue
help the surgeon to differentiate between healthy tissue and
tumor under the high magnification microscopic view. In
the case of tonsillar cancer, the lymphatic tissue structure
and any associated chronic inflammatory reaction within
the tonsils may make this assessment more difficult [14].
When following the tumor laterally, high magnification and
low CO2 laser power settings should be used because of the
proximity to the large vessels. If a safe, complete resection
via the transoral approach cannot be achieved, an external
approach should be undertaken or combined with the TLM.
Tumors were resected under the microscope with surgical
resection margins in healthy tissue of at least 5–10 mm. If the
histopathological analysis (frozen section) of the resected
specimen showed a positive resection margin, an additional
resection was carried out to obtain a clear margin.
87 % of these patients underwent a selective neck dis-
section of the levels II and III because they presented with:
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(1) advanced primary disease or (2) the tumor infiltration
depth was[3 mm at transoral resection, or (3) preoperative
imaging revealed suspicious lymph nodes Patients under-
went bilateral neck dissection if imaging revealed suspi-
cious lymph nodes bilaterally, or if suspicious lymph
nodes were seen only on one side, but no adjuvant
(chemo)radiotherapy was planned. This elective selective
neck dissection was usually performed 8–10 days after
resection of the primary. This regime and time scale have
the substantial advantage of avoiding any fistulas and add
the possibility to do a re-resection in cases where postop-
erative histopathology shows that clear margins were not
reached during the first TLM procedure.
Adjuvant radio(chemo-)therapy was administered in cases
of pN2 neck disease (pN2a, pN2b) or when the histopatholo-
gical examination revealed extracapsular spread or lymp-
hangiosis carcinomatosa. Patients were followed up with a
regular interval on an outpatient basis. Examination was
undertaken of the oral cavity and oropharynx under micro-
scopic magnification, palpation of the resection area, a rigid
90 or 70 endoscopy of the larynx and the lower parts of the
pharynx as well as a ultrasonographic examination of the neck.
All survival rates were calculated with a 95 % confidence
interval using the Kaplan–Meier method. The main points
assessed as end points were overall survival, recurrence-free
survival, disease-specific survival, local and loco-regional
control, distant metastases and second primaries. Overall
survival was calculated on deaths from all possible causes and
disease-specific survival on deaths from tonsil cancer and
deaths from therapy. For the purposes of the statistics,
recurrence-free survival, intercurrent deaths, deaths due to
secondary primary tumors, and patients alive without recur-
rences were regarded as censored observations. Events
included local and/or regional recurrences, distant metastases
and deaths due to disease. For the calculation of local control
rate, only local recurrences were considered as events, while
patients alive without local recurrence or death regardless of
reason were counted as censored. The definition of local
recurrence included carcinoma in situ as well as a carcinoma
occurring after completion of primary treatment. All events
were measured from the day of surgery to the date of their
occurrence or the date of the last follow-up. For all statistical




One hundred and two patients were eligible for this study,
with age ranging from 30 to 82 years, a median age of
57 years, and a median follow-up period of 63 months. All
102 patients were staged according to the UICC/AJCC [15]
classification, exact pT/pN-category distribution is detailed
in Table 1.
3 patients (3 %) were exclusively treated with transoral
laser surgery, 32 (31 %) with laser surgery and neck dis-
section, 65 (64 %) with laser surgery, neck dissection and
adjuvant (chemo)radiotherapy and two patients (2 %) with
laser surgery and adjuvant (chemo)radiotherapy. Neck
dissection was performed unilaterally in 78 cases (80 %)
and bilaterally in 19 cases (20 %). Most (87 %) were
selective neck dissections of levels II and III. 11 of 97
(11 %) were treated by modified radical neck dissection.
Adjuvant radio(chemo-)therapy was administered in 67
patients (66 %).
Adjuvant (chemo)radiotherapy was mainly performed in
cases of advanced neck disease (N2a/b/c) or when the
histopathological examination revealed extracapsular
spread and/or lymphatic micrometastases. From 10/1987 to
12/1994 (23 patients), the (chemo)radiotherapy schedule
was composed of two fractions per day, separated by 6-h
intervals. Each fraction consisted of 210 cGy (1.25 MV
60CO) preceded by a dose of 50 mg/m2 carboplatin i.v.
daily. A total radiation dose of 5,670 cGy was applied to
the neck and the primary tumor over 6 weeks as split-
course regimen. A break of 2 weeks was planned between
the 2 last weeks of treatment. Treatment was given 4 days
a week. Cisplatinum-based chemotherapy was given con-
comitantly in 11 cases.
From 01/1995 to 12/2004 (38 patients), normofraction-
ated radiotherapy (2 Gy/d, 5 times/week) was delivered as
follows: parallel, opposed lateral portals were applied,
matched to a single anterior portal encompassing the pri-
mary tumor and associated nodal drainage sites up to a
maximum dose of 50 Gy. Finally, a 3D conformal external
beam radiotherapy technique was used to boost the total
dose to 60 Gy, including the primary tumor and involved
lymph nodes. The spinal cord was limited to a maximum of
45 Gy. Concomitant chemotherapy was applied in seven
cases.
From 12/2004 to 12/2006 (3 patients) normofractionated
(2 Gy/d, five times/week) 3D conformal external beam
radiotherapy was given with concomitant Cisplatinum-
based chemotherapy. The primary tumor and involved
Table 1 pT/pN-category distribution
cN0 pN0 pN1 pN2a pN2b pN2c Total
pT1 0 3 7 4 8 0 22
pT2 2 8 3 0 11 0 24
pT3 3 14 5 1 19 3 42
pT4a 0 3 1 1 7 2 14
Total 30 16 6 45 5 102
Eur Arch Otorhinolaryngol (2013) 270:2299–2306 2301
123
lymph nodes and potential drainage sites on both sides of
the neck, including the supraclavicular region, were cov-
ered with 50 Gy in a first phase followed by a boost up to a
total dose of 64 Gy, including the primary tumor and
involved lymph nodes. The spinal cord was limited to a
maximum of 45 Gy.
Oncological results
Because of the relatively small numbers of patients, stages I
and II were combined for statistical analysis. The 5-year
Kaplan–Meier estimates for overall survival were 59 % for
pT1 and pT2, 56 % for pT3 and pT4 (Fig. 1). The corre-
sponding figures for 5-year recurrence-free survival were
64 % for stages pT1 and pT2 and 60 % for pT3 and pT4.
Disease-specific survival was measured as 74 % for pT1 and
pT2 and 68 % for pT3 and pT4 (Fig. 2). Local control and
loco-regional control were combined for statistical analysis.
5-year local control and loco-regional control rates were 78 %
for pT1 and pT2 and 75 % for pT3 and pT4a tumors (Fig. 3).
At the time of this analysis, 42 patients were alive with
no evidence of disease (41 %), 31 patients (30 %) had died
TNM-related, 10 patients died from second primary tumors
(10 %) and another 19 (19 %) died of intercurrent disease.
18 (18 %) local and 7 (7 %) loco-regional failures occur-
red, while four patients (4 %) had late and six (6 %)
recurrent neck metastases. An incidence of 21 second
primaries (21 %) was observed, among which ten occurred
Fig. 1 Kaplan–Meier
estimates for 10-year overall
survival
Fig. 2 Kaplan–Meier
estimates for 10-year disease-
specific survival
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in the head and neck region, five in the lung, four in the
gastro-intestinal tract and two in the prostate. Distant
metastases without simultaneous local, loco-regional or
regional recurrence were observed in six cases (6 %). Only
8 of the 32 patients with local, loco-regional or regional
failure could be successfully salvaged.
Complications and functional results
The main complication was postoperative bleeding, which
occurred 18 times. Fourteen hemorrhages (15 %) originated
postoperatively in the oropharynx and were managed by a
transoral microscopic approach with coagulation or clipping.
Four hemorrhages (4 %) occurred postoperatively in the neck
after neck dissection and were treated by neck revision. One
patient sustained significant temporary laryngeal edema
postoperatively, which was successfully treated conserva-
tively. One temporary tracheotomy due to aspiration but no
permanent tracheotomy was necessary as part of the treat-
ment in all 102 cases. The median duration of nasogastric
feeding tube placement was 10 days in 64 patients (63 %),
with a minimum of 2 days and a maximum of 129 days. In
this group, the nasogastric tube had to be replaced by gas-
trostomy tubes in four patients (4 %) because of swallowing
difficulties, two of them permanently. Another six patients
required gastrostomy tubes after adjuvant radiotherapy, one
permanently. No patient died of treatment related causes.
Discussion
Due to the lack of prospective randomized trials and site-
specific analyses, currently there is no consensus regarding
management of tonsillar squamous cell carcinomas.
Although several retrospective investigations have been
published, discussion of the oncologic outcomes is still
controversial, since evaluation of evidence supporting the
effectiveness of one treatment over the other is complicated
by a very heterogenous group of cancers (tonsil vs. oro-
pharynx), variable T/N categories, different outcome
measures and statistics.
For the treatment of tonsillar carcinomas, different sur-
gical techniques have been described including conven-
tional surgery [16], TLM [10], transoral robotic surgery
[17] and transoral lateral oropharyngectomy [18]. All these
approaches have its inherent advantages and disadvantages.
In the past, however, surgical intervention often has been
open en bloc resection to the pharynx with radical man-
dibular osteotomy after lip lysis including tracheotomy and
radical neck dissection. In contrast, TLM is a minimally
invasive surgical technique that combines radical onco-
logical treatment with relatively rapid recovery and low
side effects. Since the introduction of TLM for the treat-
ment of limited head and neck malignancies [19], indica-
tions for its use have been vastly expanded to all tumor
categories of the upper aero-digestive tract [10–13] by
Steiner in the early eighties.
Recent studies [20–22] have demonstrated that TLM in
combination with adjuvant treatment provides excellent
survival and swallowing proficiency for early and advanced
tonsillar squamous cell carcinomas. Haughey et al. [21]
investigated 204 patients with stage III and IV oropha-
ryngeal carcinoma. Ninety-eight patients presented with
tonsillar cancer and were primarily treated with TLM in
combination with or without neck dissection and adjuvant
therapy. 5-year overall, disease-specific and disease-free
survival rates of all patients were 78, 84 and 74 %. Cor-
roborating the value of TLM in treatment of tonsillar
Fig. 3 Kaplan–Meier
estimates for 10-year local
control
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cancer, Grant et al. [20] observed comparable results in 69
patients with T1–T3 oropharyngeal cancer. Twenty-eight
patients presented with tonsillar carcinoma. All patients
were primarily treated with TLM in combination with uni-
or bilateral neck dissection (83 %) and adjuvant radio-
therapy (36 %). For stage I, II, and III disease, the 5-year
Kaplan–Meier estimates of loco-regional control were 90,
73, and 70 %, respectively. The 5-year overall survival
estimate was 86 %.
In the present study, the achieved 5-year overall survival
estimates were 59 % for pT1 and pT2 tumors and 56 % for
category pT3 and pT4. Five-year local control and loco-
regional control rates were 78 % for pT1 and pT2 and
75 % for pT3 and pT4a tumors. However, as indicated at
the beginning data are fairly comparable since results of
diverse studies originate from a very heterogenous group of
cancers.
While the oncological results are comparable to more
radical interventions, a major advantage of TLM is the
relatively low morbidity. This is made possible by the
transoral approach under high microscopic magnification
with preservation of functionally important structures and
avoidance of dismantling the musculoskeletal infrastruc-
ture of the oral cavity and the pharynx. Recently, Rich et al.
[23] investigated swallowing function after TLM with or
without neck dissection and adjuvant therapy for 58
patients with advanced tonsillar cancer. Longitudinal
analysis of swallowing revealed that 1 month postopera-
tively 82 % had good swallowing. At 3 months postoper-
atively, which coincided with the administration of
adjuvant therapy, the percentage of patients with good
swallowing dropped to 55 % and rose to 89 % by the end
of 12 months.
Comparably, Haughey et al. [21] observed the preva-
lence of gastrostomy tubes after TLM as primary treatment
in patients with advanced stage III/IV oropharyngeal can-
cer as 18.8 % after 1 year, 9.3 % after 2 years and 3.4 %
after 3 years. In line with this data, Grant et al. [20]
investigated gastrostomy tube use after TLM in 69 patients
with oropharyngeal caner (tonsil n = 28). No patient nee-
ded a permanent gastrostomy tube.
In our series, the median duration of nasogastric feeding
tube placement was 10 days in 64 patients (63 %) and had
to be replaced by gastrostomy tubes in four patients (4 %)
because of swallowing difficulties, two of them perma-
nently. In both patients, advanced tumor resections
including parts of the tongue base and the hypopharynx had
to be performed. Another six patients required gastrostomy
tubes during adjuvant radiotherapy, one permanently.
Therefore, in cases of postoperative swallowing impair-
ment and planned adjuvant treatment, temporary placement
of a gastrostomy tube may be considered to improve
nutrition during radiotherapy. However, this decision has to
be taken individually for each case by the surgeon and the
patient. Even evaluation of function is not only a matter of
whether a patient is still on a nasogastric or gastrostomy
tube, it may serve as indicator for functional outcomes and
corroborates the value of TLM as primary therapy of ton-
sillar cancer.
In our series, we experienced 18 postoperative bleedings
that were managed without tracheotomy. In one case of
aspiration, a temporary tracheotomy had to be performed,
no permanent tracheotomy was needed. In recent literature
using TLM for resection of oropharyngeal cancer, rates of
tracheotomy depend on T-category and range between
0.1 % [20] and 16 % [21]. However, the decision for or
against tracheotomy has to be taken individually by the
surgeon under consideration of the medical demands and
its own demands for safety.
TLM is also an appropriate approach for patients who
require microvascular free tissue transfer because of large
vessel exposure or extended pharyngeal or palatine defects.
In addition, for resection of T3–T4 tumors large wounds
are created which may lead to severe scar tissue formation
and if the pterygoid muscles are involved also trismus
might occur. In these situations significant functional
recovery with free flap reconstruction is possible and
necessary [24]. However, in our retrospective case series,
no free tissue transfer was needed since functional out-
comes after primary healing were satisfying.
Cervical lymph node metastasis is an important prog-
nostic factor in patients with tonsillar cancer since nodal
disease significantly decreases survival rates [25]. There-
fore, neck dissection is a useful procedure in terms of
staging and for the indication of further adjuvant treatment.
Patients with occult nodal disease may be identified or
confirmed to be pN0. However, there is controversy with
regard to the elective neck treatment of contralateral neck
nodes. Chung et al. [26] investigated 76 cases with tonsillar
cancer (81.6 % stages III–IV) and found an overall con-
tralateral metastasis rate of 40.9 %. Lim et al. [27] ana-
lyzed 43 patients with pT1–pT4 tonsillar cancer and found
contralateral metastasis in 16 % of all patients. Recently,
Mantsopoulos et al. [28] investigated the surgical treatment
of locally limited pT1 and pT2 tonsillar carcinomas. In 202
patients a bilateral neck dissection was carried out in 77
cases, and contralateral neck metastases were found in
11.7 % (9 cases). However, in the majority of cases
patients presented already with clinically positive contra-
lateral lymph nodes. In cases with only positive ipsilateral
side, incidence of contralateral metastasis was only 3 %. In
our cohort, 55 % of the patients presented with advanced
pT3–pT4 tumors. Selective neck dissection was performed
unilaterally in 78 cases (80 %) and bilaterally in 19
cases (20 %). In five cases (5 %) of advanced disease,
bilaterally positive lymph nodes were found. In line with
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Mantsopoulos et al. [28], dissection of the contralateral
neck side in locally limited tonsillar tumors may be
reserved for cN2c status.
Survival and functional outcomes of primary chemora-
diation have never been tested against surgical approaches,
especially TLM, in randomized controlled trials. Results
from retrospective case series using chemoradiation com-
pare not favorably but show significant acute and chronic
toxicity due to high-dose radiotherapy often sensitized to an
even greater functional impact by concurrent chemother-
apy. Nonetheless, chemoradiation has been promoted as
treatment of choice for oropharyngeal and tonsillar carci-
nomas. Mendenhall et al. [7] reported 503 tonsillar cancers,
most of them stages III and IV, treated with radiotherapy
(RT) alone (61 %) or with RT and salvage neck dissection
(39 %). Five-year overall survival is reported as 54 % for
stage I, 61 % for stage II, 62 % for stage III and 57 % for
stage IVa. These rates are comparable with our own find-
ings. However, treatment protocols show high rates of acute
and chronic toxicity [29, 30] such as swallowing dysfunc-
tion. Perez et al. [31] investigated 384 patients presenting
with all stages of tonsillar carcinoma (80 % T3–T4) which
were treated with RT alone (n = 154), with irradiation
followed by surgery (n = 144) and with adjuvant irradia-
tion (n = 86). In patients with advanced T3–T4 tumors,
surgery in combination with adjuvant treatment offered
better tumor control than single-modality or preoperative
irradiation procedures. However, at this point of time, no
concurrent chemotherapy was offered. In line with these
results, Poulsen et al. [32] investigated 148 with curable
stage III and stage IV squamous cell carcinoma of the
tonsil. One hundred and two patients were treated with
conventional surgery ± adjuvant (chemo-)radiotherapy, 46
patients were treated with primary (chemo)radiation.
Analyses showed that patients after surgery ± (chemo-
)radiotherapy had a significantly superior overall survival
(57 vs. 41 %) and a trend towards better loco-regional
control (88 5 vs. 73 %). In a retrospective chart review,
Lamarre et al. [33] investigated 17 patients who underwent
radical tonsillectomies with neck dissection ± (chemo-
)radiotherapy, and 33 patients underwent (chemo)radiation-
based treatments for T1 and T2 and N0 to N2a tonsil cancer.
Five-year overall survival for patients undergoing primary
surgery ± adjuvant treatment and primary radiation-based
treatment did not show any statistical significant differ-
ences. However, treatment groups were small and thus may
be underpowered. Johansen et al. [34] investigated a total of
289 patients with carcinoma of the oropharynx mainly
(58 %) originating in the tonsil area. Only eight patients
were treated with primary surgery, all others were treated by
primary radiotherapy. The authors reported a recurrence of
the primary tumor in 72 %, a 5-year loco-regional control, a
disease-specific control and an overall survival of 38, 44
and 31 % which is inferior to our results. In early stage
tonsillar disease, brachytherapy can achieve high local
control and overall survival rates, the 5-year estimates being
98 and 76 % respectively with limited soft-tissue toxicity
and no reported xerostomia or osteonecrosis [35]. The
patients in this series were selected according to the thera-
peutic regimen, with 41 of 44 T1 and T2 tumors having no
neck disease (N0). Good local control (100 % 2-year esti-
mate) was achieved in a series of 24 patients treated using
targeted intra-arterial chemoradiation according to the
RADPLAT protocol, though a high rate of acute toxicity
and complications was noted. Fifty percent of the patients
developed grade 2 or 3 mucositis and three patients died
during treatment [36].
To reduce xerostomia and other local side effects in our
patients, only ipsilateral radiotherapy was used in cancers
that did not cross the midline. This is in line with results
reported by Jackson et al. [37] and Chronowski et al. [38]
that point to a reduction of acute and late side effects,
especially xerostomia, by sparing the contralateral parotid
gland, while achieving oncological results comparable to
standard radiotherapy. Using intensity modulated radio-
therapy (IMRT) could be a way to reduce late dysphagia
after such intensive chemoradiation, by partially sparing
the pharyngeal constrictor muscles, which seem to be one
reason for the mentioned swallowing problems [39].
In conclusion patients treated by TLM for squamous cell
cancer of the tonsil have a low peri-/postoperative mor-
bidity and complication rate. Only 2 % suffered from
therapy-associated swallowing problems that required a
permanent gastrostomy tube. No permanent tracheotomy
was necessary in our patients. Our results and data from the
literature show that oncological results achieved with TLM
are at least comparable to any other current surgical and
non-surgical treatment regimen. It is our opinion that TLM
in combination with or without neck dissection and adju-
vant therapy is an efficient option in the treatment of tonsil
cancer. As these results originate from a single institution
and a relatively small sample, they should be validated by
multicenter prospective clinical trials.
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